Voyager Therapeutics shares are trading higher after HC Wainwright & Co initiated coverage on the stock with a Buy rating and announced a $30 price target.
Portfolio Pulse from Benzinga Newsdesk
Voyager Therapeutics' stock price increased following HC Wainwright & Co's initiation of coverage with a Buy rating and a $30 price target.
March 19, 2024 | 3:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Voyager Therapeutics' stock price is likely to experience a short-term increase following the positive analyst coverage and ambitious price target set by HC Wainwright & Co.
Analyst ratings, especially from reputable firms, can significantly influence investor sentiment and stock prices. The initiation of coverage with a Buy rating and a high price target suggests a strong bullish outlook for Voyager Therapeutics, likely leading to increased investor interest and a rise in stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100